Phospho-ATXN1 (S776) Antibody

What is the significance of ATXN1 S776 phosphorylation in neurodegeneration research?

ATXN1 S776 phosphorylation represents a critical post-translational modification that fundamentally alters the protein's stability and interactions. This phosphorylation site is highly conserved among species and plays a pivotal role in spinocerebellar ataxia type 1 (SCA1) pathogenesis . Research has demonstrated that phosphorylation at S776 stabilizes ATXN1 protein throughout the brain, rendering it less susceptible to degradation, which is particularly problematic for polyglutamine-expanded mutant ATXN1 .

The significance of this phosphorylation extends beyond mere protein stabilization, as it enhances ATXN1's interactions with other proteins, notably the molecular chaperone 14-3-3 and the splicing factor RBM17 . These interactions are particularly enhanced with polyglutamine-expanded ATXN1, contributing to neurotoxicity in SCA1. Consequently, S776 phosphorylation is considered a viable therapeutic target, whereby blocking kinase activity targeting S776 could promote ATXN1 protein clearance and potentially alleviate SCA1 pathology .

What techniques can effectively measure ATXN1 S776 phosphorylation in tissue samples?

Several complementary techniques can effectively quantify ATXN1 S776 phosphorylation:

• Western blotting: Using phospho-specific antibodies against ATXN1-S776, researchers can detect and quantify phosphorylated ATXN1 in tissue lysates. This approach has been successfully employed to measure phosphorylation across different brain regions including cerebellum, brainstem, and hippocampus .

• Immunohistochemistry/Immunofluorescence: These techniques allow visualization of phosphorylated ATXN1 in tissue sections, enabling assessment of phosphorylation status at the cellular and subcellular levels. Serial dilutions of anti-ATXN1-phospho-S776 antibodies (such as PN1168) have been used to achieve semi-quantitative results .

• Cell-free phosphorylation assays: Cerebellar extract-based phosphorylation assays using GST-ATXN1 as substrate can measure kinase activity targeting S776 and evaluate the effects of various inhibitors .

• ELISA: This technique offers quantitative measurement of phosphorylated ATXN1 in solution and allows for high-throughput screening of samples .

For optimal results, sample preparation should include phosphatase inhibitors to prevent dephosphorylation during processing. Appropriate controls, including phosphorylation-resistant ATXN1-A776 mutants and samples from ATXN1-knockout animals, should be incorporated to validate assay specificity .

How should researchers validate the specificity of Phospho-ATXN1 (S776) antibodies?

Rigorous validation of Phospho-ATXN1 (S776) antibodies should follow this multi-step approach:

• Phosphorylation-state specificity:

  • Compare reactivity between phosphorylated and non-phosphorylated forms of ATXN1

  • Test antibody against samples treated with phosphatases

  • Use phosphorylation-resistant mutants (ATXN1-A776) as negative controls

• Protein specificity:

  • Validate using ATXN1 knockout tissues (Atxn1−/−) as negative controls

  • Test cross-reactivity against similar phospho-motifs in other proteins

  • Perform immunoblotting after immunoprecipitation to confirm binding to ATXN1

• Application-specific validation:

  • For Western blot: Confirm single band at correct molecular weight (~86 kDa)

  • For IHC/IF: Compare staining pattern with total ATXN1 distribution

  • For all applications: Use dilution series to determine optimal working concentration

• Epitope verification:

  • Confirm recognition of the specific epitope (aa 742-791 for some antibodies)

  • Verify epitope conservation when using antibodies across species

Studies have demonstrated that antibodies like PN1168 specifically detect phospho-S776-ATXN1 without cross-reactivity to other proteins, as evidenced by absence of signal in ATXN1-knockout mice and ATXN1[82Q]-A776 mutants .

What are the optimal conditions for using Phospho-ATXN1 (S776) antibodies in Western blot applications?

For optimal Western blot detection of phosphorylated ATXN1-S776:

Sample preparation:

• Extract proteins using buffers containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and phosphatase inhibitor cocktail)

• Include protease inhibitors to prevent ATXN1 degradation

• Nuclear fractionation may enhance detection, as phosphorylated ATXN1 is predominantly nuclear

Protocol optimization:

• Protein loading: 20-50 μg total protein per lane

• Recommended dilution range: 1:500-1:2000 for most commercial antibodies

• Transfer conditions: Use PVDF membrane (rather than nitrocellulose) for better protein retention

• Blocking: 5% BSA in TBST (not milk, which contains phosphatases) for 1 hour at room temperature

• Primary antibody incubation: Overnight at 4°C

Controls to include:

• Phosphorylation-resistant ATXN1-A776 as negative control

• ATXN1 knockout tissue as specificity control

• Total ATXN1 antibody (such as 11750) on parallel blots to normalize phospho-signal

Signal detection:

• Enhanced chemiluminescence is suitable for most applications

• For quantitative analysis, consider using fluorescent secondary antibodies with a scanner/imager that offers linear dynamic range

Studies have successfully employed Western blotting to detect phospho-S776-ATXN1 across various brain regions including cerebellum, brainstem, and hippocampus .

How can researchers effectively design experiments to identify kinases responsible for ATXN1 S776 phosphorylation?

Designing robust experiments to identify ATXN1 S776 kinases requires multiple complementary approaches:

• In vitro kinase assays:

  • Develop a cell-free phosphorylation assay using recombinant GST-ATXN1 and tissue extracts (cerebellar extracts have proven effective)

  • Use phospho-specific antibodies to detect S776 phosphorylation

  • Add candidate kinase inhibitors to identify potential enzymes involved

  • Include phosphorylation-resistant mutants (GST-ATXN1-A776) as controls

• Kinase fractionation approach:

  • Fractionate tissue extracts using techniques such as ammonium sulfate precipitation and chromatography (e.g., hydroxyapatite columns)

  • Test fractions for S776 kinase activity

  • Correlate activity peaks with the presence of specific kinases via immunoblotting

  • Confirm findings with specific kinase inhibitors and immunodepletion

• Immunodepletion studies:

  • Deplete specific candidate kinases from extracts using antibodies

  • Measure remaining S776 phosphorylation activity

  • A significant decrease in activity suggests involvement of the depleted kinase

• In vivo verification:

  • Generate transgenic models expressing dominant-negative kinase forms

  • Assess changes in ATXN1 S776 phosphorylation

  • Evaluate the effects on ATXN1 protein levels and stability

This multi-faceted approach has successfully identified PKA as a primary ATXN1-S776 kinase in cerebellar extracts, contradicting earlier suggestions that Akt was responsible . Immunodepletion of PKA significantly reduced S776 phosphorylation, and PKA inhibitors (staurosporine and PKA Inhibitor-amide) reduced phosphorylation in a dose-dependent manner, while Akt inhibitors had no significant effect .

What controls are critical when studying the effects of S776 phosphorylation on ATXN1 protein stability?

When investigating the relationship between S776 phosphorylation and ATXN1 stability, the following controls are essential:

Critical experimental controls:

• Phosphorylation-state mutants:

  • ATXN1-S776A (phosphorylation-resistant) - demonstrates effects of complete phosphorylation absence

  • ATXN1-S776D (phosphomimetic) - simulates constitutive phosphorylation

  • Wild-type ATXN1 with normal S776 as baseline comparison

• Polyglutamine length controls:

  • Normal length (ATXN1[2Q] or ATXN1[30Q]) vs. expanded (ATXN1[82Q] or ATXN1[154Q])

  • Test phosphorylation effects on both normal and expanded proteins separately

  • This reveals potential interactions between polyQ expansion and phosphorylation

• Tissue/cell type controls:

  • Compare effects across multiple brain regions (cerebellum, brainstem, hippocampus)

  • Previous work demonstrates tissue-specific effects of S776 phosphorylation

• Transcript level measurements:

  • RT-qPCR to ensure that any changes in protein levels are post-transcriptional

  • Studies consistently show that S776A mutations don't affect mRNA levels

• Temporal controls:

  • Measure protein stability at multiple timepoints

  • Include pulse-chase experiments to distinguish between effects on synthesis vs. degradation

Using these controls, researchers have demonstrated that S776 phosphorylation stabilizes both wild-type and polyQ-expanded ATXN1 throughout the brain, with disruption of this phosphorylation reducing protein levels without affecting mRNA expression .

How does disruption of ATXN1 S776 phosphorylation differentially affect various brain regions in SCA1 models?

The effects of disrupting ATXN1 S776 phosphorylation show remarkable regional heterogeneity across the brain in SCA1 models:

Cerebellum:

• S776A mutation drastically reduces both wild-type and polyQ-expanded ATXN1 protein levels

• Complete abolishment of ATXN1 nuclear inclusions in Purkinje cells

• Significant improvement in cerebellar motor coordination phenotypes

• Restoration of normal cerebellar pathology

Brainstem:

• Reduced polyQ-expanded ATXN1 levels lead to improved respiratory function

• Partial amelioration of neuromuscular respiratory dysfunction

• Extended lifespan in SCA1 mouse models with S776A mutation on the expanded allele

• These improvements suggest brainstem-mediated functions respond favorably to reduced ATXN1 phosphorylation

Hippocampus:

• Despite reduced ATXN1 levels with S776A mutation, learning and memory deficits persist

• During Morris water maze testing, SCA1 mice with S776A mutation failed to remember platform location

• This suggests distinct pathogenic mechanisms in hippocampus that aren't solely dependent on ATXN1 levels

Interestingly, the effects appear to be allele-specific. When S776A mutation is introduced only on the polyQ-expanded allele, therapeutic benefits are more pronounced than when the mutation is present on both expanded and wild-type alleles . This suggests a potential neuroprotective role of normal phosphorylated ATXN1 and indicates that allele-specific therapeutic approaches may be most beneficial .

These findings reveal complex brain region-specific disease mechanisms in SCA1 and suggest that targeting S776 phosphorylation may have differential therapeutic effects depending on which symptoms are being addressed .

What molecular mechanisms explain how S776 phosphorylation affects ATXN1 protein stability and toxicity?

S776 phosphorylation modulates ATXN1 stability and toxicity through multiple interconnected molecular mechanisms:

• 14-3-3 protein interaction:

  • Phosphorylated S776 creates a binding site for 14-3-3 molecular chaperones

  • This interaction stabilizes ATXN1 by preventing its degradation

  • Co-expression of ATXN1[82Q] and d14-3-3ε in Drosophila enhances neurodegeneration

  • Reducing 14-3-3 levels shifts polyQ-expanded ATXN1 from large to small protein complexes in cerebellum

• Protein complex formation alterations:

  • Phosphorylation at S776 changes ATXN1's affinity for different protein partners

  • Regional differences in ATXN1-containing complexes exist between cerebellum and brainstem

  • These differences may explain why cerebellum-related motor deficits respond better to 14-3-3ε reduction than brainstem-related symptoms

• RBM17 interaction enhancement:

  • S776 phosphorylation strengthens binding to splicing factor RBM17

  • This interaction is further enhanced by polyQ expansion

  • Studies in Drosophila show RBM17 overexpression worsens retinal degeneration with mutant ATXN1[82Q]

  • Partial genetic ablation of dRBM17 attenuates pathology, suggesting the ATXN1[82Q]/RBM17 interaction is toxic

• Subcellular localization effects:

  • Phosphorylated ATXN1 is enriched in the nuclear fraction

  • Interestingly, the kinases responsible for phosphorylation (like PKA) are predominantly cytoplasmic

  • This suggests phosphorylation may occur in the cytoplasm before nuclear translocation

• Ubiquitination interference:

  • ATXN1 is normally ubiquitinated by UBE3A, leading to proteasomal degradation

  • Phosphorylation at S776 may interfere with this process

  • In SCA1 patients, polyQ expansion further impairs ubiquitination and degradation

These mechanistic insights explain why disrupting S776 phosphorylation reduces ATXN1 levels throughout the brain and provides a rationale for developing therapeutic strategies targeting this post-translational modification in SCA1 .

What experimental strategies can evaluate kinase inhibition as a therapeutic approach for SCA1?

Evaluating kinase inhibitors as potential SCA1 therapeutics requires a comprehensive experimental pipeline:

In vitro screening phase:

• Cell-free kinase assays:

  • Test candidate inhibitors using cerebellar extract-based phosphorylation assays

  • Measure S776 phosphorylation of GST-ATXN1 with phospho-specific antibodies

  • Establish dose-response relationships for promising compounds

• Cellular models:

  • Assess inhibitor effects in neuronal cell lines expressing ATXN1[82Q]

  • Measure changes in ATXN1 protein levels, S776 phosphorylation, and ATXN1 inclusions

  • Evaluate cellular toxicity endpoints and off-target effects

In vivo preclinical assessment:

• Pharmacokinetic/pharmacodynamic studies:

  • Determine CNS penetration of inhibitors

  • Measure target engagement by assessing S776 phosphorylation reduction in brain tissue

  • Establish optimal dosing regimens for sustained phosphorylation inhibition

• Efficacy in mouse models:

  • Test in SCA1 knockin mice (e.g., Atxn1 154Q/2Q models)

  • Assess multiple endpoints:

    • ATXN1 protein levels across brain regions

    • Motor coordination (rotarod, beam walking tests)

    • Respiratory function

    • Survival

    • Learning and memory (Morris water maze)

• Allele-specific considerations:

  • Compare outcomes between inhibitors that target both wild-type and mutant ATXN1 phosphorylation versus allele-specific approaches

  • Research suggests targeting only the expanded allele may be more beneficial

Biomarker development:

• Pharmacodynamic markers:

  • Develop assays to measure S776 phosphorylation in accessible samples (CSF)

  • Identify downstream molecular changes that correlate with therapeutic efficacy

Previous research demonstrated that PKA inhibitors (staurosporine and PKA Inhibitor-amide) effectively reduce S776 phosphorylation in cerebellar extracts, while Akt inhibitors were ineffective . These findings provide a foundation for developing more selective PKA inhibitors as potential SCA1 therapeutics .

How can researchers address the apparent contradiction between PKA and Akt as candidate kinases for ATXN1 S776 phosphorylation?

The contradictory findings regarding PKA and Akt as candidate kinases for ATXN1 S776 phosphorylation require systematic investigation through the following approaches:

Experimental reconciliation strategies:

• Model system comparison:

  • Systematically compare kinase activities in different model systems:

    • Drosophila models (where Akt was implicated)

    • Mammalian cell lines

    • Mouse cerebellar extracts (where PKA was identified)

    • Human patient-derived samples

  • This may reveal species-specific or cell type-specific differences in kinase preferences

• Biochemical characterization:

  • Perform in vitro kinase assays with purified PKA and Akt

  • Compare kinetic parameters (Km, Vmax) for S776 phosphorylation

  • Examine potential cofactors or scaffolding proteins that might influence specificity in different contexts

• Genetic approaches:

  • Generate conditional kinase knockouts/knockdowns for both PKA and Akt

  • Assess effects on ATXN1 S776 phosphorylation in relevant tissues

  • Create double knockout/knockdown models to examine redundancy

• Spatiotemporal resolution:

  • Investigate whether different kinases phosphorylate ATXN1 at S776 in different:

    • Subcellular compartments (cytoplasm vs. nucleus)

    • Developmental stages

    • Pathological conditions

Evidence for PKA as the predominant kinase:

Several lines of evidence support PKA as the primary S776 kinase in the cerebellum:

• PKA co-fractionates with the S776 kinase activity in cerebellar cytosol under both ammonium sulfate and hydroxyapatite fractionation conditions

• PKA inhibitors (staurosporine and PKA Inhibitor-amide) significantly reduce S776 phosphorylation in a dose-dependent manner

• 50% immunodepletion of PKA from cerebellar extracts significantly reduces phosphorylation of ATXN1-S776

• In contrast, immunodepletion of Akt did not significantly affect S776 phosphorylation

• Expression of dominant-negative Akt in Purkinje cells did not inhibit S776 phosphorylation but actually increased phospho-S776-ATXN1 levels

These findings suggest that while Akt might phosphorylate ATXN1 in some contexts, PKA appears to be the predominant S776 kinase in the cerebellum, which is a primary site of SCA1 pathology .

What novel approaches could advance our understanding of the tissue-specific effects of ATXN1 S776 phosphorylation?

Several innovative approaches could elucidate the tissue-specific effects of ATXN1 S776 phosphorylation:

• Single-cell phosphoproteomics:

  • Apply phospho-specific mass spectrometry to individual cells from different brain regions

  • Compare phosphorylation patterns between vulnerable and resistant cell populations

  • Correlate S776 phosphorylation with cell-specific transcriptomes and proteomes

• Spatial phosphorylation mapping:

  • Develop high-resolution imaging techniques using phospho-specific antibodies

  • Map ATXN1 S776 phosphorylation patterns across brain regions in SCA1 models

  • Correlate phosphorylation patterns with regional pathology progression

• Cell type-specific phosphorylation modulation:

  • Generate conditional S776A knock-in models with cell-type specific Cre drivers

  • Compare outcomes when S776 phosphorylation is disrupted in:

    • Cerebellar Purkinje cells

    • Brainstem neurons

    • Hippocampal neurons

  • This approach would determine if cellular context influences the consequences of phosphorylation

• Interactome analysis by region:

  • Compare ATXN1 protein interaction networks across brain regions

  • Identify region-specific binding partners that might explain differential effects

  • Research suggests protein complex composition differs between cerebellum and brainstem

• Multi-parametric animal models:

  • Develop models combining S776A mutation with other SCA1-related modifications

  • Investigate potential synergistic effects with:

    • 14-3-3 protein levels

    • RBM17 expression

    • Additional phosphorylation sites

Previous research has demonstrated significant differences in how S776 phosphorylation disruption affects cerebellar motor coordination, respiratory function, and hippocampal learning deficits . These novel approaches would help explain these regional differences and potentially identify region-specific therapeutic strategies.

How might allele-specific targeting of ATXN1 S776 phosphorylation be achieved for therapeutic purposes?

Developing allele-specific approaches to target S776 phosphorylation selectively on polyQ-expanded ATXN1 represents a promising therapeutic direction:

Potential strategies for allele-specific targeting:

• Antisense oligonucleotide (ASO) approaches:

  • Design ASOs targeting single-nucleotide polymorphisms (SNPs) in linkage disequilibrium with the expanded CAG repeat

  • These could selectively reduce expression of the mutant allele

  • While not directly targeting phosphorylation, this approach would decrease the substrate for phosphorylation

• CRISPR-based approaches:

  • Utilize CRISPR-Cas9 to introduce the S776A mutation specifically in the expanded allele

  • This could be achieved through homology-directed repair using the expanded CAG tract as a distinguishing feature

  • Research has shown that S776A mutation specifically on the polyQ-expanded ATXN1 allele provides optimal therapeutic benefit

• Structure-based drug design:

  • Develop small molecules that selectively bind to the region around S776 in polyQ-expanded ATXN1

  • The expanded polyQ tract may create conformational differences that could be exploited

  • These compounds could either block kinase access or recruit phosphatases specifically to the mutant protein

• Allele-specific kinase recruitment modulation:

  • Identify differences in how kinases interact with normal versus expanded ATXN1

  • Design molecules that interfere with recruitment of kinases only to the expanded protein

  • This approach would require detailed understanding of the structural consequences of polyQ expansion

Evidence supporting allele-specific approaches:

Research has shown that SCA1 animals with S776A mutation only on the expanded allele (ATXN1[154Q]) displayed greater improvement in phenotypes compared to animals with S776A mutations on both alleles . This suggests wild-type ATXN1 might have neuroprotective properties that would be preserved through allele-specific targeting .

Experiments with CRISPR/Cas9 have successfully introduced the S776A mutation into specific ATXN1 alleles in mouse models, demonstrating the technical feasibility of allele-specific genetic modification approaches .

These findings highlight the importance of developing allele-specific therapeutic strategies for maximal benefits in SCA1 treatment .

Data Tables and Technical Specifications

A comprehensive experimental approach to study ATXN1 S776 phosphorylation should integrate multiple techniques, controls, and considerations to ensure robust and reproducible results:

• Model system selection:

  • Choose appropriate models spanning in vitro to in vivo systems

  • Consider transgenic models with varying polyQ lengths

  • Include models with phosphorylation-site mutations (S776A, S776D)

  • Ensure relevance to human disease conditions

• Tissue and cell-type specificity:

  • Include multiple brain regions (cerebellum, brainstem, hippocampus)

  • Consider peripheral tissues where ATXN1 is expressed

  • Account for cell-type specific effects (Purkinje cells vs. other neurons)

• Technical approaches:

  • Combine biochemical, genetic, and imaging approaches

  • Use phospho-specific antibodies with appropriate validation

  • Include kinase activity assays and inhibitor studies

  • Employ genetic models (knockout, knockin) for mechanistic insights

• Comprehensive controls:

  • Use phosphorylation-resistant mutants (ATXN1-A776)

  • Include ATXN1 knockout tissues as negative controls

  • Measure mRNA levels to distinguish transcriptional from post-transcriptional effects

  • Consider developmental timing and age-dependent effects

• Translational considerations:

  • Assess multiple disease-relevant endpoints (motor, cognitive, survival)

  • Consider therapeutic implications of findings

  • Evaluate allele-specific effects and potential for selective targeting

This integrated approach has successfully revealed that S776 phosphorylation stabilizes ATXN1 throughout the brain, that disrupting phosphorylation specifically on polyQ-expanded ATXN1 provides optimal therapeutic benefit, and that PKA is likely the primary kinase responsible for this modification in cerebellar Purkinje cells .

What is the current consensus on the therapeutic potential of targeting ATXN1 S776 phosphorylation for SCA1?

Current evidence suggests significant therapeutic potential in targeting ATXN1 S776 phosphorylation for SCA1, with important nuances regarding implementation:

Established therapeutic benefits:

• Disrupting S776 phosphorylation reduces both wild-type and polyQ-expanded ATXN1 protein levels throughout the brain

• S776A mutation on the polyQ-expanded allele improves multiple SCA1 phenotypes:

  • Cerebellar motor coordination

  • Respiratory function

  • Survival

• Abolishing S776 phosphorylation prevents formation of nuclear inclusions in Purkinje cells

Important limitations and considerations:

• Hippocampal learning and memory deficits are not rescued by S776 phosphorylation disruption, suggesting distinct pathogenic mechanisms in different brain regions

• Optimal benefits come from selective targeting of the expanded allele; disrupting phosphorylation on both alleles provides attenuated rescue

• The wild-type ATXN1 allele appears to have neuroprotective properties that may be compromised by global phosphorylation inhibition

Potential therapeutic approaches:

• PKA inhibitors represent a promising strategy, as PKA appears to be the primary kinase responsible for S776 phosphorylation in the cerebellum

• Allele-specific strategies (genetic editing, ASOs linked to expanded polyQ tract) may provide maximal benefits

• Combination approaches targeting both phosphorylation and protein interactions (e.g., with 14-3-3 or RBM17) might offer synergistic effects